Minimal residual disease is a sensitive way to measure disease ... Historically, we evaluated myeloma through monoclonal proteins or free light chains in the blood and urine and percentage of ...

Dr Braunstein, when do you typically assess these patients for MRD status following their initial therapy? BRAUNSTEIN: I ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...

Multiple myeloma is the second most common form of hematological (blood) cancer with over 175,000 new cases diagnosed each year worldwide. The detection of MRD in patients with MM serves as one of ...

is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Tel ...

is pleased to announce that it is evaluating its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as a part of the TELO-DMRD clinical validation study. Tel ...

Chief Executive Officer of Legend Biotech. “MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma. The significantly increased overall and ...